{"id":338,"date":"2023-05-25T21:13:30","date_gmt":"2023-05-25T21:13:30","guid":{"rendered":"https:\/\/i2u.ca\/?page_id=338"},"modified":"2025-02-10T18:32:50","modified_gmt":"2025-02-10T18:32:50","slug":"our-insights","status":"publish","type":"page","link":"https:\/\/i2u.ca\/fr\/our-insights\/","title":{"rendered":"Nos id\u00e9es"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\n
\n

Nos id\u00e9es<\/strong><\/strong><\/h3>\n<\/div>\n\n
I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across Canada and in a focused group of comparator jurisdictions.<\/h6>\n\n
\n
\n
\n
\n
\n
\"\"<\/figure>\n\n

Th\u00e9rapies CAR-T<\/strong><\/h4>\n\n

Une \u00e9tude de cas r\u00e9trospective sur une nouvelle immunoth\u00e9rapie<\/p>\n\n

\u00a0<\/p>\n\n

Lire la suite<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n\n

\n
\n
\"\"<\/figure>\n\n

LUXTURNA<\/strong><\/h4>\n\n

Une \u00e9tude de cas r\u00e9trospective sur une th\u00e9rapie g\u00e9nique sp\u00e9cialis\u00e9e<\/p>\n\n

\u00a0<\/p>\n\n

Lire la suite<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n\n

\n
\n
\"\"<\/figure>\n\n

LEQEMBI<\/strong><\/h4>\n\n

Une \u00e9tude de cas prospective sur un nouveau m\u00e9dicament contre la maladie d'Alzheimer<\/p>\n\n

\u00a0<\/div>\n\n

Lire la suite<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n\n

\n
\n
\"\"<\/figure>\n\n

CRISPR<\/strong><\/h4>\n\n

A snapshot case study on CRISPR\/Cas9 Technology for Blood Disorders<\/p>\n\n

\u00a0<\/p>\n\n

Lire la suite<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n

\u00a0<\/div>\n\n
Looking across these case studies, I2U identified 7 distinct implementation challenges each with the potential to diminish the optimal patient and system impact of a given breakthrough medicine:<\/h6>\n\n
\"\"<\/figure>\n\n
\n

Recent Webinars<\/h2>\n\n
\u00a0<\/div>\n\n

January 17, 2025<\/p>\n

<\/p>\n

Helping Health Systems Better Prepare for Breakthrough Medicines: Profiling an Innovative New Tool<\/a><\/strong><\/h5>\n

<\/p>\n

\n
https:\/\/www.youtube.com\/watch?v=kAy_08AXbVg<\/div>\n<\/figure>\n

<\/p>\n

\n
Download Slides<\/a><\/div>\n
\u00a0<\/div>\n<\/div>\n

June 1, 2023<\/p>\n\n

Maximizing the Uptake of Breakthrough Medicines Across Canada: Lessons from CAR-T<\/a><\/strong><\/h5>\n\n
\n
https:\/\/www.youtube.com\/watch?v=qd_64OqEOpI<\/div>\n<\/figure>\n\n
\n
Download Slides<\/a><\/div>\n<\/div>\n<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Our Insights I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_coblocks_attr":"","_coblocks_dimensions":"{\"coblocks-feature-42619358643\":{\"padding\":{}},\"coblocks-feature-426193643732\":{\"padding\":{\"paddingBottom\":\"px\",\"paddingBottomMobile\":null,\"paddingBottomTablet\":null,\"paddingLeft\":\"0px\",\"paddingLeftMobile\":null,\"paddingLeftTablet\":null,\"paddingRight\":\"0px\",\"paddingRightMobile\":null,\"paddingRightTablet\":null,\"paddingTop\":\"px\",\"paddingTopMobile\":null,\"paddingTopTablet\":null}},\"coblocks-features-42619358527\":{\"padding\":{\"paddingBottom\":\"px\",\"paddingBottomMobile\":null,\"paddingBottomTablet\":null,\"paddingLeft\":\"0px\",\"paddingLeftMobile\":null,\"paddingLeftTablet\":null,\"paddingRight\":\"0px\",\"paddingRightMobile\":null,\"paddingRightTablet\":null,\"paddingTop\":\"px\",\"paddingTopMobile\":null,\"paddingTopTablet\":null}}}","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","hide_page_title":"","footnotes":""},"class_list":["post-338","page","type-page","status-publish","hentry"],"yoast_head":"\nOur Insights - I2U<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/i2u.ca\/fr\/our-insights\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Our Insights - I2U\" \/>\n<meta property=\"og:description\" content=\"Our Insights I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/i2u.ca\/fr\/our-insights\/\" \/>\n<meta property=\"og:site_name\" content=\"I2U\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-10T18:32:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i2u.ca\/wp-content\/uploads\/2023\/05\/virus.png\" \/>\n\t<meta property=\"og:image:width\" content=\"64\" \/>\n\t<meta property=\"og:image:height\" content=\"64\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/\",\"url\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/\",\"name\":\"Our Insights - I2U\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i2u.ca\\\/wp-content\\\/uploads\\\/2023\\\/05\\\/virus.png\",\"datePublished\":\"2023-05-25T21:13:30+00:00\",\"dateModified\":\"2025-02-10T18:32:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i2u.ca\\\/wp-content\\\/uploads\\\/2023\\\/05\\\/virus.png\",\"contentUrl\":\"https:\\\/\\\/i2u.ca\\\/wp-content\\\/uploads\\\/2023\\\/05\\\/virus.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/our-insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/i2u.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Our Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/#website\",\"url\":\"https:\\\/\\\/i2u.ca\\\/\",\"name\":\"I2U\",\"description\":\"Accelerating the Journey from Idea to Utilization\",\"publisher\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/i2u.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/#organization\",\"name\":\"I2U\",\"url\":\"https:\\\/\\\/i2u.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/i2u.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i2u.ca\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/I2U-Main-Logo.png\",\"contentUrl\":\"https:\\\/\\\/i2u.ca\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/I2U-Main-Logo.png\",\"width\":413,\"height\":275,\"caption\":\"I2U\"},\"image\":{\"@id\":\"https:\\\/\\\/i2u.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Our Insights - I2U","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/i2u.ca\/fr\/our-insights\/","og_locale":"fr_CA","og_type":"article","og_title":"Our Insights - I2U","og_description":"Our Insights I2U has created several case studies to identity and illuminate the discrete challenges preventing the value maximization of breakthrough medicines, and lessons learned for future innovations. To uncover these challenges, I2U conducted interviews with a wide range of system leaders and stakeholders, supported by extensive background research on implementation challenges and approaches across […]","og_url":"https:\/\/i2u.ca\/fr\/our-insights\/","og_site_name":"I2U","article_modified_time":"2025-02-10T18:32:50+00:00","og_image":[{"width":64,"height":64,"url":"https:\/\/i2u.ca\/wp-content\/uploads\/2023\/05\/virus.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/i2u.ca\/our-insights\/","url":"https:\/\/i2u.ca\/our-insights\/","name":"Our Insights - I2U","isPartOf":{"@id":"https:\/\/i2u.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/i2u.ca\/our-insights\/#primaryimage"},"image":{"@id":"https:\/\/i2u.ca\/our-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/i2u.ca\/wp-content\/uploads\/2023\/05\/virus.png","datePublished":"2023-05-25T21:13:30+00:00","dateModified":"2025-02-10T18:32:50+00:00","breadcrumb":{"@id":"https:\/\/i2u.ca\/our-insights\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/i2u.ca\/our-insights\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/i2u.ca\/our-insights\/#primaryimage","url":"https:\/\/i2u.ca\/wp-content\/uploads\/2023\/05\/virus.png","contentUrl":"https:\/\/i2u.ca\/wp-content\/uploads\/2023\/05\/virus.png"},{"@type":"BreadcrumbList","@id":"https:\/\/i2u.ca\/our-insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/i2u.ca\/"},{"@type":"ListItem","position":2,"name":"Our Insights"}]},{"@type":"WebSite","@id":"https:\/\/i2u.ca\/#website","url":"https:\/\/i2u.ca\/","name":"I2U","description":"Acc\u00e9l\u00e9rez le parcours de l'id\u00e9e \u00e0 l'utilisation","publisher":{"@id":"https:\/\/i2u.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/i2u.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/i2u.ca\/#organization","name":"I2U","url":"https:\/\/i2u.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/i2u.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i2u.ca\/wp-content\/uploads\/2022\/08\/I2U-Main-Logo.png","contentUrl":"https:\/\/i2u.ca\/wp-content\/uploads\/2022\/08\/I2U-Main-Logo.png","width":413,"height":275,"caption":"I2U"},"image":{"@id":"https:\/\/i2u.ca\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/pages\/338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/comments?post=338"}],"version-history":[{"count":45,"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/pages\/338\/revisions"}],"predecessor-version":[{"id":796,"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/pages\/338\/revisions\/796"}],"wp:attachment":[{"href":"https:\/\/i2u.ca\/fr\/wp-json\/wp\/v2\/media?parent=338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}